West Pharmaceutical Services Property, plant, and equipment additions decreased by 32.5% to $42.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 40.1%, from $71.30M to $42.70M.
Higher spending indicates growth investment or infrastructure upgrades, while lower spending may signal capital preservation.
The total capital investment made to acquire or improve long-lived assets, such as property, plant, and equipment. This...
Standard metric for capital-intensive industries like manufacturing and consumer goods.
other_segment_expenditure_addition_to_long_lived_assets| Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|
| Value | $90.60M | $100.20M | $81.30M | $71.30M | $75.20M | $63.30M | $42.70M |
| QoQ Change | — | +10.6% | -18.9% | -12.3% | +5.5% | -15.8% | -32.5% |
| YoY Change | — | — | — | -21.3% | -25.0% | -22.1% | -40.1% |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Proprietary Products | $58.50M | $47.80M | $79.10M | $51.90M | $48.50M | $47.70M | $56.20M | $36.50M |
| West Vantage | — | — | — | — | — | — | — | $5.60M |
| Contract-Manufactured Products | $39.20M | $30.00M | $24.20M | $18.10M | $25.50M | $13.60M | $18.30M | — |
| Total | $100.20M | $81.30M | — | $71.30M | $75.20M | $63.30M | — | $42.70M |
Contract-Manufactured Products was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.